CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus Erythematosus

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
This is a phase I, open-label, single-arm, multicenter study to asess the safety tolerability pharmacokinetics and pharmacodynamics of Relma-cel in moderate or severe active systemic lupus erythematosus (SLE) subjects in China.
Epistemonikos ID: da98fb9b6f9116ed2754ddd6fdab688c8c6c3c48
First added on: May 14, 2024